Palvella Therapeutics, Inc. (PVLA) Free Cash Flow (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Free Cash Flow for 12 consecutive years, with -$5.4 million as the latest value for Q4 2024.
- On a quarterly basis, Free Cash Flow fell 125.95% to -$5.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$10.8 million, a 21.19% increase, with the full-year FY2024 number at -$10.8 million, up 21.19% from a year prior.
- Free Cash Flow was -$5.4 million for Q4 2024 at Palvella Therapeutics, down from -$2.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $29.7 million in Q2 2021 to a low of -$22.9 million in Q1 2022.
- A 5-year average of -$7.1 million and a median of -$10.7 million in 2020 define the central range for Free Cash Flow.
- Peak YoY movement for Free Cash Flow: surged 373.8% in 2021, then tumbled 154.92% in 2022.
- Palvella Therapeutics' Free Cash Flow stood at -$14.0 million in 2020, then grew by 24.44% to -$10.6 million in 2021, then decreased by 22.21% to -$12.9 million in 2022, then soared by 259.66% to $20.6 million in 2023, then crashed by 125.95% to -$5.4 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Free Cash Flow are -$5.4 million (Q4 2024), -$2.7 million (Q3 2024), and -$1.6 million (Q2 2024).